2. Academic Validation
  3. A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer

A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer

  • Cell Rep Med. 2025 Jul 15;6(7):102233. doi: 10.1016/j.xcrm.2025.102233.
Florian Dilasser 1,  Lindsay Rose 1,  Agnès Quemener 2,  Yann Ferrandez 3,  Dorian Hassoun 1,  Morgane Rousselle 1,  Hugo Bergereau 1,  Séverine Marionneau Lambot 2,  Luciano E Anselmino 4,  Camille Trouillet 5,  Gwennan Andre 1,  Mike Maillasson 6,  Mikael Croyal 7,  Matthieu Riviere 5,  Didier Dubreuil 5,  Sylvain Collet 5,  Frédérique Souaze 2,  Mario Campone 2,  Anne Patsouris 2,  Erwan Mortier 6,  Mauricio Menacho Marquez 4,  Philippe Juin 2,  Jacques Lebreton 5,  Arnaud Tessier 5,  Jacqueline Cherfils 3,  Gervaise Loirand 8,  Vincent Sauzeau 9
Affiliations

Affiliations

  • 1 Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes F-44000, France.
  • 2 Nantes Université, Inserm, CNRS, CRCI(2)NA, Nantes F-44000, France.
  • 3 Laboratory of biology and applied pharmacology, CNRS, ENS Paris-Saclay, Paris, France.
  • 4 Instituto de Inmunología Clínica y Experimental de Rosario (IDICER CONICET-UNR), Centro de Investigación del Cáncer de Rosario. Facultad de Ciencias Médicas, Rosario, Santa Fe 3100, Argentina.
  • 5 Nantes Université, CNRS, CEISAM, UMR 6230, Nantes F-44000, France.
  • 6 Nantes Université, Inserm, CNRS, CRCI(2)NA, Nantes F-44000, France; Nantes Université, CHU Nantes, CNRS, Inserm, BioCore, US16, SFR Bonamy, Nantes, France.
  • 7 Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes F-44000, France; Nantes Université, CHU Nantes, CNRS, Inserm, BioCore, US16, SFR Bonamy, Nantes, France.
  • 8 Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes F-44000, France. Electronic address: gervaise.loirand@univ-nantes.fr.
  • 9 Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes F-44000, France. Electronic address: vincent.sauzeau@univ-nantes.fr.
PMID: 40633540 DOI: 10.1016/j.xcrm.2025.102233
Abstract

The dysregulation of RAC1 activity is associated with neoplastic transformation, metastasis, and poor prognosis in several cancers. Here, we discover in silico a series of RAC1 inhibitors. The most potent of them, A41, specifically inhibits RAC1 with an original mechanism of action. We characterize A41 as a reversible inhibitor that competes with guanine nucleotide binding specifically on RAC proteins. A41 efficiently blocks RAC1 activity and RAC1-dependent cell functions including cell adhesion and migration. Chronic administration of A41 exhibits anti-metastatic effects in mouse models of triple-negative breast Cancer, leading to an increase in the survival rate. Our findings suggest that this molecule, A41, could be a promising and powerful therapeutic agent for limiting invasive cancers in patients.

Keywords

RAC1; drug discovery; invasive cancer; triple-negative breast cancer.

Figures
Products